Cat. No.: HY-136506

NUC-7738

Name: NUC-7738
Brand: MedChemExpress
SKU: HY-136506
Price: 220.00 USD
Availability: InStock
Rating: 5 (1 reviews)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

NUC-7738, an aryloxy phosphoramidate of 3′-Deoxyadenosine, is a 5′-aryloxy phosphoramidate prodrug of 3′-Deoxyadenosine (3′-dA). NUC-7738 has potent cytotoxic activity against a panel of hematological cancer cell lines. NUC-7738 can be used in research of cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 97.01%
CAS No.: 2348493-39-8
Formule: C₂₆H₂₉N₆O₇P
Masse moléculaire:568.52

Stockage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

NUC-7738 Chemical Structure

CAS No.: 2348493-39-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

HY-N0262
Cordycepin

Bacterial Inhibitor

Activité biologique
- Description
- Cellular Effect
- In Vitro
- Essai clinique
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Cellular Effect

Cell Line	Type	Value	Description	References
5637	IC₅₀	47.45 μM Compound: NUC7738	Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
A498	IC₅₀	58.05 μM Compound: NUC7738	Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
CAKI-2	IC₅₀	102.45 μM Compound: NUC7738	Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
COLO 205	IC₅₀	27.75 μM Compound: NUC7738	Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HepG2	IC₅₀	25.24 μM Compound: NUC7738	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HL-60	IC₅₀	38.4 μM Compound: NUC7738	Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HT-29	IC₅₀	9.47 μM Compound: NUC7738	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
K562	IC₅₀	10.34 μM Compound: NUC7738	Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
KG-1	IC₅₀	23.51 μM Compound: NUC7738	Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MCF7	IC₅₀	3.69 μM Compound: NUC7738	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MDA-MB-231	IC₅₀	19.42 μM Compound: NUC7738	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MIA PaCa-2	IC₅₀	7.41 μM Compound: NUC7738	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MOLT-4	IC₅₀	4.67 μM Compound: NUC7738	Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
PC-3	IC₅₀	51.18 μM Compound: NUC7738	Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
RL	IC₅₀	34.65 μM Compound: NUC7738	Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]

In Vitro

NUC-7738 (compound 7a; 0-198 μM; 72 h; CCRF-CEM, HL-60, KG-1, MOLT-4, K562, MV4-11, THP-1, HEL92, NCI-H929, RPMI-8226, Jurkat, Z138, RL, HS445, HepG2, MCF-7, Bx-PC-3, HT29, MIA PaCa-2 and SW620 cells) has anticancer activity and cytotoxic activity against a lineage of leukocytes with LC₅₀ values of ＜30 μM^[1].
NUC-7738 (1 μM) has good stability in human hepatocytes with t_1/2 value of 48.1 min^[1].
NUC-7738 has increased stability in human plasma compared to the parent nucleoside, with no change in plasma concentration up to 4 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2348493-39-8
Appearance Solid
Masse moléculaire 568.52
Formule C₂₆H₂₉N₆O₇P
Color White to off-white
SMILES

NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](COP(N[C@@H](C)C(OCC4=CC=CC=C4)=O)(OC5=CC=CC=C5)=O)C[C@H]3O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

J Biochem Mol Toxicol

NUC7738 Induces Apoptosis Through Modulating Stability of P53 in Esophageal Cancer Cells. [Abstract]

2025 Feb;39(2):e70175. PMID: 39967332

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (175.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7590 mL

8.7948 mL

17.5895 mL

5 mM

0.3518 mL

1.7590 mL

3.5179 mL

10 mM

0.1759 mL

0.8795 mL

1.7590 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Serpi M, et, al. Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent. J Med Chem. 2022 Dec 8;65(23):15789-15804. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7590 mL	8.7948 mL	17.5895 mL	43.9738 mL
	5 mM	0.3518 mL	1.7590 mL	3.5179 mL	8.7948 mL
	10 mM	0.1759 mL	0.8795 mL	1.7590 mL	4.3974 mL
	15 mM	0.1173 mL	0.5863 mL	1.1726 mL	2.9316 mL
	20 mM	0.0879 mL	0.4397 mL	0.8795 mL	2.1987 mL
	25 mM	0.0704 mL	0.3518 mL	0.7036 mL	1.7590 mL
	30 mM	0.0586 mL	0.2932 mL	0.5863 mL	1.4658 mL
	40 mM	0.0440 mL	0.2199 mL	0.4397 mL	1.0993 mL
	50 mM	0.0352 mL	0.1759 mL	0.3518 mL	0.8795 mL
	60 mM	0.0293 mL	0.1466 mL	0.2932 mL	0.7329 mL
	80 mM	0.0220 mL	0.1099 mL	0.2199 mL	0.5497 mL
	100 mM	0.0176 mL	0.0879 mL	0.1759 mL	0.4397 mL

Bioz

Keywords

NUC-7738

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

NUC-7738

Publications Citing Use of MedChemExpress (MCE) NUC-7738